Glenmark Launches Lobeglitazone (thiazolidinedione lobeglitazone) for Uncontrolled Type 2 Diabetes in India
Shots:
- The company launches Lobeglitazone (0.5mg) in India to treat T2D in adults. The product will be marketed under the brand name LOBG & and will be sold for ₹10/tablet to improve glycemic control in adult diabetic patients
- The DCGI has approved to manufacture and marketing of Lobeglitazone, based on the results from the P-III trial in T2D patients aged ≥18yrs. which showed a faster and improved glycaemic control with lobeglitazone
- In 2019, the company launched Remogliflozin, a novel SGLT‐2 inhibitor after its first global approval in India and also launched its combinations with metformin and Vildagliptin
Ref: Glenmark | Image: Glenmark
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
